These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 20621731)
1. Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Dewang PM; Kim DK Bioorg Med Chem Lett; 2010 Jul; 20(14):4228-32. PubMed ID: 20621731 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Jung SH; Lee HS; Dewang PM Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Jang Y; Lee HS; Park HJ; Yoo J J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors. Kim DK; Choi JH; An YJ; Lee HS Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787 [TBL] [Abstract][Full Text] [Related]
9. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase. Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5). Li X; Wang L; Long L; Xiao J; Hu Y; Li S Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5). Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase. Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor beta 1 type 1 receptor. Kim DK; Kim J; Park HJ Bioorg Med Chem Lett; 2004 May; 14(10):2401-5. PubMed ID: 15109621 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047 [TBL] [Abstract][Full Text] [Related]
16. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917 [TBL] [Abstract][Full Text] [Related]
19. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor beta1 type 1 receptor. Kim DK; Kim J; Park HJ Bioorg Med Chem; 2004 May; 12(9):2013-20. PubMed ID: 15080905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]